Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:TRIL Trillium Therapeutics (TRIL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Trillium Therapeutics Stock (NASDAQ:TRIL) 30 days 90 days 365 days Advanced Chart Get Trillium Therapeutics alerts:Sign Up Key Stats Today's Range$18.44▼$18.4450-Day Range$17.50▼$18.4452-Week Range$5.80▼$20.96Volume8 shsAverage Volume1.87 million shsMarket Capitalization$1.94 billionP/E Ratio29.74Dividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewTrillium Therapeutics, Inc. is a clinical stage immuno-oncology company, which engages in the research and development of therapies for the treatment of cancer. It offers clinical programs, TTI-621 and TTI-622, target CD47, a signal that cancer cells frequently use to evade the immune system. The company was founded on March 31, 2004 and is headquartered in Mississauga, Canada.Read More… Receive TRIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Trillium Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address TRIL Stock News HeadlinesWhen You Look Back in 5 Years, You'll Wish You'd Bought This $2 Trillion Artificial Intelligence (AI) StockJuly 30, 2024 | finance.yahoo.comLeiomyosarcoma Drug Pipeline Report 2023 - ResearchAndMarkets.comNovember 10, 2023 | businesswire.comDOGE To DO ListElon's found so much waste he's now claiming "the magnitude of the fraud in federal entitlements" is greater than "the combined sum of every private scam you've ever heard by FAR"... And while this is disturbing and even infuriating to see our tax money literally wasted... there IS a solution. I believe it's Elon's ultimate end game.February 18, 2025 | Altimetry (Ad)Mirati Therapeutics Stock (NASDAQ:MRTX), Analyst Ratings, Price Targets, PredictionsNovember 8, 2023 | benzinga.comThe Global T-Cell therapy Market size is expected to reach $9.2 billion by 2030, rising at a market growth of 17.5% CAGR during the forecast periodJuly 31, 2023 | uk.finance.yahoo.comWHO Red Flags Punjab-Made Cough Syrup In Fresh Alert: 'Can Cause Even Death'April 26, 2023 | msn.comLeukemia Therapeutics Global Market Report 2023April 4, 2023 | uk.finance.yahoo.comRatio Therapeutics Announces Licensing Agreement for Investigational PET Imaging Agent with MerckMarch 28, 2023 | finance.yahoo.comSee More Headlines TRIL Stock Analysis - Frequently Asked Questions How were Trillium Therapeutics' earnings last quarter? Trillium Therapeutics Inc. (NASDAQ:TRIL) issued its quarterly earnings data on Thursday, November, 18th. The biotechnology company reported ($0.18) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.01. What other stocks do shareholders of Trillium Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Trillium Therapeutics investors own include NVIDIA (NVDA), CannaPharmaRX (CPMD), FuelCell Energy (FCEL), Gilead Sciences (GILD), TG Therapeutics (TGTX), Inovio Pharmaceuticals (INO) and Advanced Micro Devices (AMD). Company Calendar Last Earnings11/18/2021Today2/18/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:TRIL CUSIPN/A CIK1616212 Webwww.trilliumtherapeutics.com Phone(416) 595-0627FaxN/AEmployees33Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)$0.62 Trailing P/E Ratio29.74 Forward P/E RatioN/A P/E GrowthN/ANet Income$-59,350,000.00 Net MarginsN/A Pretax Margin-113,720.92% Return on Equity-23.31% Return on Assets-18.66% Debt Debt-to-Equity RatioN/A Current Ratio19.82 Quick Ratio19.82 Sales & Book Value Annual Sales$150,000.00 Price / Sales12,907.39 Cash FlowN/A Price / Cash FlowN/A Book Value$2.56 per share Price / Book7.20Miscellaneous Outstanding Shares104,995,000Free Float95,440,000Market Cap$1.94 billion OptionableOptionable Beta2.08 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.Get This Free Report This page (NASDAQ:TRIL) was last updated on 2/18/2025 by MarketBeat.com Staff From Our PartnersTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredDOGE To DO ListElon's found so much waste he's now claiming "the magnitude of the fraud in federal entitlements" is greater t...Altimetry | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredMarket down? Do this now.During Trump's first term, his tariffs sent gold prices soaring. Investors who acted early made a fortune. Now...Colonial Metals | SponsoredThree new patents reveal Elon and Trump’s secret “Project America”Right now for a limited time… You can get Tim Bohen’s top 5 Trump stocks for 2025… For only ONE DOLLAR!...Timothy Sykes | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | Sponsored50-year legend: Here’s exact day stocks will crashBig Study Shows Stocks Extremely Likely to Crash in 2026? Legendary quant analyst Marc Chaikin says in 50 y...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Trillium Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Trillium Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
